Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease

Lyndsey E. Collins, Nicholas E. Paul, Shams F. Abbas, Chelsea E. Leser, Samantha J. Podurgiel, Daniel J. Galtieri, James J. Chrobak, Younis Baqi, Christa E. Müller, John D. Salamone

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Anticholinesterases are the most common treatment for Alzheimer's disease, and, in recent years, a new group of cholinesterase inhibitors (i.e. rivastigmine, galantamine, and donepezil) has become available. Although these drugs improve cognitive symptoms, they also can induce or exacerbate parkinsonian symptoms, including tremor. The present studies were conducted to determine if galantamine induces tremulous jaw movements, a rodent model of parkinsonian tremor, and to investigate whether these oral motor impairments can be reversed by co-administration of adenosine A 2A antagonists. The first experiment demonstrated that systemic injections of galantamine (0.75-6.0 mg/kg I.P.) induced a dose-related increase in tremulous jaw movements in rats. In a second study, co-administration of the muscarinic antagonist scopolamine (0.0156-0.25 mg/kg I.P.) produced a dose dependent suppression of tremulous jaw movements induced by a 3.0 mg/kg dose of galantamine, indicating that galantamine induces these tremulous oral movements through actions on muscarinic acetylcholine receptors. In two additional studies, analyses of freeze-frame video and electromyographic activity recorded from the lateral temporalis muscle indicated that the local frequency of these galantamine-induced jaw movements occurs in the 3-7 Hz frequency range that is characteristic of parkinsonian tremor. In the final experiment, the adenosine A 2A antagonist MSX-3 significantly attenuated the tremulous jaw movements induced by the 3.0 mg/kg dose of galantamine, which is consistent with the hypothesis that co-administration of adenosine A 2A antagonists may be beneficial in reducing parkinsonian motor impairments induced by anticholinesterase treatment.

Original languageEnglish
Pages (from-to)414-422
Number of pages9
JournalPharmacology Biochemistry and Behavior
Volume99
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Galantamine
Tremor
Cholinergic Agents
Rats
Alzheimer Disease
Jaw
Cholinesterase Inhibitors
Adenosine
Rivastigmine
Neurobehavioral Manifestations
Muscarinic Antagonists
Scopolamine Hydrobromide
Muscarinic Receptors
Muscle
Rodentia
Experiments
Muscles
Injections
Therapeutics

Keywords

  • Acetylcholine
  • Adenosine A2A
  • Basal ganglia
  • Muscarinic
  • Parkinsonism
  • Tremulous jaw movements

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

Oral tremor induced by galantamine in rats : A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. / Collins, Lyndsey E.; Paul, Nicholas E.; Abbas, Shams F.; Leser, Chelsea E.; Podurgiel, Samantha J.; Galtieri, Daniel J.; Chrobak, James J.; Baqi, Younis; Müller, Christa E.; Salamone, John D.

In: Pharmacology Biochemistry and Behavior, Vol. 99, No. 3, 09.2011, p. 414-422.

Research output: Contribution to journalArticle

Collins, LE, Paul, NE, Abbas, SF, Leser, CE, Podurgiel, SJ, Galtieri, DJ, Chrobak, JJ, Baqi, Y, Müller, CE & Salamone, JD 2011, 'Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease', Pharmacology Biochemistry and Behavior, vol. 99, no. 3, pp. 414-422. https://doi.org/10.1016/j.pbb.2011.05.026
Collins, Lyndsey E. ; Paul, Nicholas E. ; Abbas, Shams F. ; Leser, Chelsea E. ; Podurgiel, Samantha J. ; Galtieri, Daniel J. ; Chrobak, James J. ; Baqi, Younis ; Müller, Christa E. ; Salamone, John D. / Oral tremor induced by galantamine in rats : A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. In: Pharmacology Biochemistry and Behavior. 2011 ; Vol. 99, No. 3. pp. 414-422.
@article{814ad6925ba14cd0bf406370b39521f3,
title = "Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease",
abstract = "Anticholinesterases are the most common treatment for Alzheimer's disease, and, in recent years, a new group of cholinesterase inhibitors (i.e. rivastigmine, galantamine, and donepezil) has become available. Although these drugs improve cognitive symptoms, they also can induce or exacerbate parkinsonian symptoms, including tremor. The present studies were conducted to determine if galantamine induces tremulous jaw movements, a rodent model of parkinsonian tremor, and to investigate whether these oral motor impairments can be reversed by co-administration of adenosine A 2A antagonists. The first experiment demonstrated that systemic injections of galantamine (0.75-6.0 mg/kg I.P.) induced a dose-related increase in tremulous jaw movements in rats. In a second study, co-administration of the muscarinic antagonist scopolamine (0.0156-0.25 mg/kg I.P.) produced a dose dependent suppression of tremulous jaw movements induced by a 3.0 mg/kg dose of galantamine, indicating that galantamine induces these tremulous oral movements through actions on muscarinic acetylcholine receptors. In two additional studies, analyses of freeze-frame video and electromyographic activity recorded from the lateral temporalis muscle indicated that the local frequency of these galantamine-induced jaw movements occurs in the 3-7 Hz frequency range that is characteristic of parkinsonian tremor. In the final experiment, the adenosine A 2A antagonist MSX-3 significantly attenuated the tremulous jaw movements induced by the 3.0 mg/kg dose of galantamine, which is consistent with the hypothesis that co-administration of adenosine A 2A antagonists may be beneficial in reducing parkinsonian motor impairments induced by anticholinesterase treatment.",
keywords = "Acetylcholine, Adenosine A2A, Basal ganglia, Muscarinic, Parkinsonism, Tremulous jaw movements",
author = "Collins, {Lyndsey E.} and Paul, {Nicholas E.} and Abbas, {Shams F.} and Leser, {Chelsea E.} and Podurgiel, {Samantha J.} and Galtieri, {Daniel J.} and Chrobak, {James J.} and Younis Baqi and M{\"u}ller, {Christa E.} and Salamone, {John D.}",
year = "2011",
month = "9",
doi = "10.1016/j.pbb.2011.05.026",
language = "English",
volume = "99",
pages = "414--422",
journal = "Pharmacology, Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Oral tremor induced by galantamine in rats

T2 - A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease

AU - Collins, Lyndsey E.

AU - Paul, Nicholas E.

AU - Abbas, Shams F.

AU - Leser, Chelsea E.

AU - Podurgiel, Samantha J.

AU - Galtieri, Daniel J.

AU - Chrobak, James J.

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Salamone, John D.

PY - 2011/9

Y1 - 2011/9

N2 - Anticholinesterases are the most common treatment for Alzheimer's disease, and, in recent years, a new group of cholinesterase inhibitors (i.e. rivastigmine, galantamine, and donepezil) has become available. Although these drugs improve cognitive symptoms, they also can induce or exacerbate parkinsonian symptoms, including tremor. The present studies were conducted to determine if galantamine induces tremulous jaw movements, a rodent model of parkinsonian tremor, and to investigate whether these oral motor impairments can be reversed by co-administration of adenosine A 2A antagonists. The first experiment demonstrated that systemic injections of galantamine (0.75-6.0 mg/kg I.P.) induced a dose-related increase in tremulous jaw movements in rats. In a second study, co-administration of the muscarinic antagonist scopolamine (0.0156-0.25 mg/kg I.P.) produced a dose dependent suppression of tremulous jaw movements induced by a 3.0 mg/kg dose of galantamine, indicating that galantamine induces these tremulous oral movements through actions on muscarinic acetylcholine receptors. In two additional studies, analyses of freeze-frame video and electromyographic activity recorded from the lateral temporalis muscle indicated that the local frequency of these galantamine-induced jaw movements occurs in the 3-7 Hz frequency range that is characteristic of parkinsonian tremor. In the final experiment, the adenosine A 2A antagonist MSX-3 significantly attenuated the tremulous jaw movements induced by the 3.0 mg/kg dose of galantamine, which is consistent with the hypothesis that co-administration of adenosine A 2A antagonists may be beneficial in reducing parkinsonian motor impairments induced by anticholinesterase treatment.

AB - Anticholinesterases are the most common treatment for Alzheimer's disease, and, in recent years, a new group of cholinesterase inhibitors (i.e. rivastigmine, galantamine, and donepezil) has become available. Although these drugs improve cognitive symptoms, they also can induce or exacerbate parkinsonian symptoms, including tremor. The present studies were conducted to determine if galantamine induces tremulous jaw movements, a rodent model of parkinsonian tremor, and to investigate whether these oral motor impairments can be reversed by co-administration of adenosine A 2A antagonists. The first experiment demonstrated that systemic injections of galantamine (0.75-6.0 mg/kg I.P.) induced a dose-related increase in tremulous jaw movements in rats. In a second study, co-administration of the muscarinic antagonist scopolamine (0.0156-0.25 mg/kg I.P.) produced a dose dependent suppression of tremulous jaw movements induced by a 3.0 mg/kg dose of galantamine, indicating that galantamine induces these tremulous oral movements through actions on muscarinic acetylcholine receptors. In two additional studies, analyses of freeze-frame video and electromyographic activity recorded from the lateral temporalis muscle indicated that the local frequency of these galantamine-induced jaw movements occurs in the 3-7 Hz frequency range that is characteristic of parkinsonian tremor. In the final experiment, the adenosine A 2A antagonist MSX-3 significantly attenuated the tremulous jaw movements induced by the 3.0 mg/kg dose of galantamine, which is consistent with the hypothesis that co-administration of adenosine A 2A antagonists may be beneficial in reducing parkinsonian motor impairments induced by anticholinesterase treatment.

KW - Acetylcholine

KW - Adenosine A2A

KW - Basal ganglia

KW - Muscarinic

KW - Parkinsonism

KW - Tremulous jaw movements

UR - http://www.scopus.com/inward/record.url?scp=79958279401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958279401&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2011.05.026

DO - 10.1016/j.pbb.2011.05.026

M3 - Article

C2 - 21640750

AN - SCOPUS:79958279401

VL - 99

SP - 414

EP - 422

JO - Pharmacology, Biochemistry and Behavior

JF - Pharmacology, Biochemistry and Behavior

SN - 0091-3057

IS - 3

ER -